Evidence map›Paper›PMID 42246622›Full record

ArticleArchiv der Pharmazie2026

Design, Synthesis, and Anticancer Evaluation of Febuxostat-Based Triazolyl Derivatives.

Yao Lu, Han Wang, Dong Yan, Baoyu He, Jingjing Guo, Xixi Hou, Ling Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archiv der Pharmazie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yao LuCollege of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, Henan, China.ORCID https://orcid.org/0009-0005-5260-1312
Han WangCollege of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, Henan, China.
Dong YanCollege of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, Henan, China.
Baoyu HeCentre for Artificial Intelligence-Driven Drug Discovery, Faculty of Applied Sciences, Macao Polytechnic University, Macao SAR, China.
Jingjing GuoCentre for Artificial Intelligence-Driven Drug Discovery, Faculty of Applied Sciences, Macao Polytechnic University, Macao SAR, China.
Xixi HouDepartment of Pharmacy, the First Affiliated Hospital and College of Clinical Medicine, Henan University of Science and Technology, Luoyang, Henan, China.
Ling LiuCollege of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, Henan, China.ORCID https://orcid.org/0000-0003-3043-6676

Funding

Scientific Research Fund of Henan University of Science and Technology 4020/13480023
6 · The paper itself

Abstract

Febuxostat, a selective xanthine oxidase inhibitor, was modified via 1,2,3-triazole-based molecular hybridization to generate a series of derivatives with potential anticancer activity. Among them, compounds 8c and 8e exhibited significant antitumor effects across multiple cancer cell lines, particularly in HepG2 cells, with IC

Indexed as

Antineoplastic AgentsDrug DesignFebuxostatTriazolesAnimalsApoptosisCell Line, TumorCell ProliferationDNA DamageDose-Response Relationship, DrugHep G2 CellsHumansMiceMice, Inbred BALB CMice, NudeMolecular StructureAntineoplastic AgentsFebuxostatTriazolesXanthine Oxidase1,2,3‐triazolecell apoptosisDNA damagefebuxostatγ‐H2AX

Identifiers

PMID42246622
PMCPMC13238814

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.